



From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

Alexandria TM Lee ¹, Saihong Ignatius Ou ^{1,2}

¹University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA; ²Chao Family Comprehensive Cancer Center, Orange, CA, USA

Correspondence: Saihong Ignatius Ou, University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, 200 South Manchester, Suite 400, Orange, CA, 92868, USA, Email siou@hs.uci.edu

Abstract: The competing roles of various next-generation ALK TKIs in the first and second line treatment setting of advanced *ALK*+ NSCLC were based on many phase 3 clinical trials in both the first-line and crizotinib-refractory settings. The approval of all next-generation ALK TKIs was first in the crizotinib-refractory setting, based on a large-scale Phase 2 trial, and was then followed by at least one global randomized phase 3 trial comparing to platinum-based chemotherapy (ASCEND-4) or to crizotinib (ALEX, ALTA-1L, eXalt3, CROWN). In addition, three randomized phase 3 trials in the crizotinib-refractory setting were also conducted by next-generation ALK TKIs that were developed earlier before the superiority of next-generation ALK TKIs was demonstrated in order to secure the approval of these ALK TKIs in the crizotinib-refractory setting. These three crizotinib-refractory randomized trials were: ASCEND-5 (ceritinib), ALUR (alectinib), and ALTA-3 (brigatinib). The outcome of the ALTA-3 trial was recently presented closing out the chapter where next-generation ALK TKIs were investigated in the crizotinib-refractory setting as they have replaced crizotinib as the standard of care first-line treatment of advanced *ALK*+ NSCLC. This editorial summarizes the results of next-generation ALK TKIs in randomized crizotinib-refractory trials and provides a perspective on how natural history of *ALK*+ NSCLC may potentially be altered with sequential treatment. ALTA-3 compared brigatinib to alectinib, showing that both achieved near identical blinded independent review committee (BIRC)-assessed progression-free survival (PFS) (19.2–19.3 months). Importantly, 4.8% of brigatinib-treated patients developed interstitial lung disease (ILD) while no alectinib-treated patients developed ILD. Dose reduction and discontinuation due to treatment-related adverse events were 21% and 5%, respectively, for brigatinib-treated patients compared to 11% and 2%, respectively, for alectinib-treated patients. Upon analysis of these findings, we speculate that brigatinib may have a diminishing role in the treatment of advanced *ALK*+ NSCLC.

Keywords: ALTA-3, ALUR, ASCEND-5, brigatinib, alectinib, ceritinib, crizotinib, advanced *ALK*+ NSCLC

Introduction

When crizotinib received full FDA approval based on the results of the PROFILE 1007 trial, in which crizotinib demonstrated statistically significant improvement in progression-free survival over single-agent chemotherapy (pemetrexed or docetaxel) in the second-line chemotherapy-refractory setting,^{1,2} the US FDA approval was not contingent on any particular line of therapy setting.² Notably, the initially accelerated US FDA approval of crizotinib on August 26, 2011, was described broadly as “treatment of advanced anaplastic lymphoma kinase fusion positive (*ALK*+) non-small cell lung cancer (NSCLC).³ Nevertheless, crizotinib quickly demonstrated statistically significant improvement in progression-free survival over platinum-based chemotherapy and established itself as the standard of care (SOC) treatment of advanced *ALK*+ NSCLC in 2014.⁴

As data of multiple on-target resistance mutations and lack of substantial central nervous system efficacy emerged from the use of crizotinib, more potent next-generation ALK tyrosine kinase inhibitors (TKIs) based on lower concentration to inhibit 50% of the ALK kinase activity (IC_{50}) were developed to overcome resistance to crizotinib.⁵ The clinical development of these next-generation ALK TKIs followed the now very standard drug development paradigm, with, first, a phase 2, usually single arm study, demonstrating an impressive overall response rate (ORR) and secondarily long duration of response (DOR) in a molecularly defined cohort of crizotinib-refractory patients. Importantly, all US FDA accelerated approvals require at least one randomized phase 3 trial demonstrating clinical benefit. Given that crizotinib had, by this point, established statistically significant improvement in PFS in the first-line setting (PROFILE1014),⁴ in addition to the chemotherapy-refractory setting (PROFILE1007),¹ randomized phase 3 trials involving next generation ALK TKIs had to be designed with a specific line of therapy in mind. While the pharmaceutical sponsor of ALK TKIs aimed to replace crizotinib as the new first-line SOC treatment of advanced *ALK+* NSCLC, given that the initial approval status of next-generation ALK TKIs were in the crizotinib-refractory setting and the still nascent knowledge base of advanced *ALK+* NSCLC, three randomized phase 3 trials in the crizotinib-refractory were launched and subsequently completed (ASCEND-5,⁶ ALUR,^{7,8} and ALTA-3).^{9,10} The most recent trial, ALTA-3, reported its results at the ESMO Asia 2022 meeting.

Randomized Second-Line Trials of Next-Generation ALK TKI in Crizotinib-Refractory Settings

ASCEND-5 (NCT01828112)

ASCEND-5 is an open-label randomized trial comparing ceritinib to either single-agent pemetrexed or docetaxel chemotherapy in the post-platinum-based chemotherapy AND post-crizotinib progression settings. The conduct and results of this trial are listed in Table 1. The median PFS achieved by ceritinib was 5.4 months (95% CI: 4.1–6.9), which was significantly better than single-agent chemotherapy, with a median PFS of 1.6 months (1.4–2.8). The hazard ratio of these results was 0.49 (95% CI: 0.36–0.67); $p < 0.0001$.⁶ The ASCEND-5 results confirmed the accelerated approval of ceritinib for crizotinib-refractory ALK TKI.¹¹

ALUR (NCT02604342)

ALUR is a randomized phase 3 trial designed similarly to ASCEND-5 and compared alectinib to single agent docetaxel or pemetrexed chemotherapy.⁷ The primary data from ALUR are listed in Table 1. Blinded independent review committee (BIRC)-assessed PFS was significantly longer with alectinib, with a HR of 0.32 (95% CI: 0.17–0.59). Median PFS was 7.1 months (95% CI: 6.3–10.8) with alectinib and 1.6 months (95% CI: 1.3–4.1) with chemotherapy. The final update of ALUR indicated further prolongation of the investigator-assessed PFS of alectinib from 9.6 months⁷ to 10.9 months⁸ with no change in the BIRC-assessed PFS for alectinib (Table 1).

ALTA-3 (NCT03596866)

Given that ALTA-3 was launched later than ASCEND-5 and ALUR, the use of ceritinib, alectinib, and brigatinib was approved in the crizotinib-refractory setting. Also, the stated purpose of ALTA-3 from the sponsor and clinical investigators was as follows: “if positive, the results of ALTA-3 will build on the ALTA trial data and reaffirm the optimal approach with brigatinib over alectinib in crizotinib-resistant patients”.⁹ Hence in ALTA-3, *ALK+* NSCLC patients were randomized 1:1 to either alectinib or brigatinib. ALTA-3 employed two stratification factors, the presence/absence of brain metastases and the best response to crizotinib (CR/PR versus SD/PD/other). While prior chemotherapy was allowed in ALTA-3, prior use of chemotherapy was not a stratification factor. Additionally, ALTA-3 was a globally conducted trial, but race (Asian vs non-Asian) was not a stratification factor. The sample size was calculated to be 246 total patients (164 events) to detect improvement in median PFS from 9 to 15 months (HR=0.60). Interim analysis for efficacy and futility was to be conducted at approximately 70% of target PFS events (~115 of 164 expected events).^{9,10}

ALTA-3 was a well-conducted trial, although with a list of patient characteristics that could affect the trial outcome, but were not stratification factors, including sex, race, smoking history, performance status, prior systemic chemotherapy (31% for brigatinib and 35% for alectinib), and distribution of tumor metastasis (Table 1). Furthermore, median time from initial

Table 1 Comparison of Characteristics of ASCEND-5, ALUR, and ALTA-3

	ASCEND-5 (NCT01828112)		ALUR (NCT02604342)		ALTA-3 (NCT03596866)	
Trial Design						
	Ceritinib	Docetaxel/ pemetrexed	Alectinib	Docetaxel/ Pemetrexed	Brigatinib	Alectinib
N (# patients)	115	116	72	35	125	123
Date of enrollment	June 28, 2013 (started) November 2, 2015 (ended)		September 28, 2018 (ended)			
Stratification factors	WHO PS (0 vs 1–2) and presence of brain metastases at screening (yes vs no).		ECOG PS (0/1 vs 2); baseline CNS metastases (yes vs no); and, for patients with baseline CNS metastases, brain radiotherapy history (yes vs no)		Brain metastases at baseline (yes vs no) and best response to prior crizotinib (CR/PR vs SD/PD/other)	
Randomization ratio	1:1		2:1		1:1	
Primary endpoint	IRC-assessed PFS		Investigator-assessed PFS		BIRC-assessed PFS	
Cross-over	Allowed		Allowed		Not allowed	
Trial conduct						
Number of lines of chemotherapy	1 line (88%) 2 lines (11%)	1 line (88%) 2 lines (12%)	1 line (100%)	1 line (100%)	1 line (31%)	1 line (35%)
% CNS metastasis	57%	59%	65.3%	74.3%	64%	61%
Never-smoker	62%	53%	48.6%	45.7%	66%	69%
Trial outcome						
BIRC-ORR (95% CI)	39.1% (30.2–48.7)	6.9% (3.0–13.1)			52 (43–61)	61 (52–70)
BIRC-PFS (95% CI)	5.4 (4.1–6.9)	1.6 (1.4–2.8)	7.1 (6.3–10.8)	1.6 (1.3–4.1)	19.3 (15.7–NR)	19.2 (12.9–NR)
BIRC-PFS HR (95% CI)	0.49 (0.36–0.67); $p < 0.0001$		0.32 (0.17–0.59)		0.97 (0.66–1.42); $p = 0.8672$	
Investigator-assessed PFS	6.9 (4.4–7.9)	1.6 (1.4–2.6)	10.9 (8.1–15.5)	1.4 (1.2–1.6)	16.8m (10.9–19.4)	16.6 (13.6–27.6)
Investigator-assessed PFS HR (95% CI)	0.40 (0.29–0.54)		0.2 (10.2–0.33); $p < 0.0001$		1.23 (95% CI: 0.86–1.76)	
OS (95% CI)	18.1m (13.4–23.9)	20.1m (11.9–25.1)	12.6m (95% CI=9.7–NR)	NR (95% CI=NR–NR)	1-year survival probability: brigatinib, 89% (95% CI=81–93)	1-year survival probability: alectinib, 96% (95% CI=90–98)
OS HR	0.50		0.89 (95% CI: 0.35–2.24)		NA	

Abbreviations: BIRC, blinded independent review committee; CI, confidence interval; IRC, independent review committee; M, month; NA, not available; NR, not reached; OS, overall survival; PFS, progression-free survival; PS, performance status.

diagnosis of *ALK*+ NSCLC and time on treatment with crizotinib, though longer, were similar. Plasma genotyping was successful in 94.4% (118/125) of brigatinib-treated patients and 92.7% (114/123) of alectinib-treated patients.

The primary endpoint of the trial BIRC-assessed median PFS was identical, with 19.2 months in the alectinib-treated patients (95% CI: 12.9–not reached) and 19.3 months in the brigatinib-treated patients (95% CI: 15.7–not reached). The HR achieved by brigatinib-treated patients was 0.97 (95% CI: 0.66–1.42); $p=0.8672$)¹⁰ (Table 1). Other important endpoints of ALTA-3 are listed in Table 1. Both next-generation *ALK* TKIs achieved median PFS beyond the expectation of clinicians.

In terms of safety, there was no treatment-related death in both treatment arms. Six out of 125 (4.8%) brigatinib-treated patients developed interstitial lung disease (ILD) (either grade 1 or 2) while no alectinib-treated patients developed ILD. Dose reduction and discontinuation due to treatment-related adverse events were 21% and 5%, respectively, for brigatinib-treated patients compared to 11% and 2%, respectively, for alectinib-treated patients. Quality-of-life improved in the brigatinib and alectinib arms beginning at cycle 2 and was not significantly different between arms. However, the majority of the time alectinib scored numerically above brigatinib. Time to worsening in the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-LC13 Composite Score was similar between arms, with a HR of 0.87 (95% CI: 0.65–1.18). In summary, overall response rate, safety as measured by dose reduction and discontinuation, and quality-of-life numerically favor alectinib over brigatinib, although these results were not statistically significant. Near-identical median PFS was achieved by both alectinib and brigatinib.

Why ALTA-3 Did Not Show Any PFS Improvement of Brigatinib Over Alectinib

The obvious question we are faced with is the reason behind alectinib's and brigatinib's essentially identical performance, given that pre-clinically brigatinib was more potent than alectinib, as demonstrated by longer median PFS in phase 2 trials.^{12–14} The only imbalance between the two arms is the proportion of *EML4-ALK* variant 1. There were nine (7.2%; 9/125) *EML4-ALK* variant 1s in the brigatinib-treated arm compared to 17 (13.8%; 17/123) *EML4-ALK* variant 1s in the alectinib-treated arm. There were similar proportions of *EML4-ALK* variant 3 in the brigatinib-treated arm (N = 16; 8.0%; 16/125) compared to the alectinib-treated arm (N = 15; 8.1%; 15/123). It is well-known that *EML4-ALK* variant 3 is more resistant to all *ALK* TKIs,¹⁵ but the similar and low incidence among the ALTA-3 populations is unlikely to favor one treatment arm over the other. Further analysis of the ORR and PFS by alectinib and brigatinib according to *EML4-ALK* variant will be required to assess how this imbalance may have contributed to the eventual outcome of ALTA-3. Future randomization should take *EML4-ALK* variant (v1 versus v3 versus other) as a stratification factor.

The detection rate of *ALK* fusion from plasma genotyping was lower than has been reported (usually >50%).¹⁶ Hence, while most of the *EML4-ALK* variants were unknown, it is unlikely that the eight known confirmed extra *EML4-ALK* variant 1s that could have conferred a difference in PFS explain the PFS seen in alectinib compared to brigatinib.

One of the more likely reasons that there was no difference between brigatinib and alectinib was that the *ALK*+ NSCLC patients enrolled into ALTA-3 possessed a better prognosis based on three characteristics. First, the median time from diagnosis of *ALK*+ NSCLC to enrollment was relatively long, with a median time in the alectinib group of 21.3 months (range: 2.37–266.2) and 22.2 months (range: 2.3–161.8) in the brigatinib group.¹⁰ We assumed that most patients were stage IV and that the time of second-line treatment from diagnosis was relatively long, at 22 months for advanced *ALK*+ NSCLC. Second and in support of our first observation, the duration of crizotinib treatment was 16.8 (range: 1.0–83.8) months for patients randomized to alectinib and 16.0 (range: 1.3–85.9) months for patients randomized to brigatinib.¹⁰ The median PFS of first-line crizotinib in PROFILE1014, ALEX, J-ALEX, ALESIA, ALTA-1L, and CROWN was between 9 and 11 months.^{4,16–20} It is likely that the duration of crizotinib treatment included continuation of crizotinib-beyond progressive disease (CBPD), especially among CNS-only patients, who represent a subgroup of patients with better prognosis. However, a median duration of 16 months in the crizotinib group is still a relatively long time, even taking into consideration CBPD.²¹ Third, the detection of *ALK* fusions in the plasma was low, at 27% for brigatinib and 40% for alectinib. The ability to detect *ALK* fusion by plasma genotyping generally represents a higher tumor burden and the positive rate of *ALK* fusions is usually >50%.¹⁵ Indeed, the median PFS between patients with detectable *ALK* fusion in plasma was only 11.1 months (95% CI: 8.0–19.3) compared to 22.5 months (95% CI: 19.2–NE) for non-detectable *ALK* fusions.

The Dwindling Role of Brigatinib in the Treatment of Advanced *ALK*+ NSCLC from the ALTA Program (ALTA, ALTA-1L, J-ALTA, ALTA-2, ALTA-3)

The first-line approval of alectinib based on ALEX was on December 11, 2017, while the first-line brigatinib approval based on ALTA-1L was on May 27, 2020, almost 30 months later. Prior to that, the approval of alectinib in crizotinib-refractory patients was on November 26, 2015, compared to the approval of brigatinib in crizotinib-refractory patients on April 28, 2017. This was, again, almost 18 months behind alectinib.¹⁵ Thus, the adaptation of brigatinib had always followed that of alectinib, and its uniquely unpredictable rapid-onset pulmonary toxicity within the first week of treatment could have further deterred many oncologists from its use.²² Thus, despite the much longer median PFS demonstrated by brigatinib in ALTA compared to the alectinib in phase 2 trials, oncologists have eagerly-awaited the ALTA-1L data.

Cross-trial comparisons are admittedly discouraged, but commonly used amongst oncologists to make certain clinical judgments. Thus, it can be said that brigatinib in ALTA-1L has failed to demonstrate a numerical advantage in median PFS (24.0 months)²³ over the median PFS of alectinib in ALEX (25.7 months).¹⁷ Given that the standard of care for advanced *ALK*+ NSCLC has advanced quickly to next-generation *ALK* TKIs, alectinib has become the primary first-line treatment of advanced *ALK*+ NSCLC. Furthermore, the number of patients treated initially with crizotinib as their first *ALK* TKI has been dwindling rapidly. Thus, the ALTA-3 data further destabilizes the market share of brigatinib in the ever-disappearing post-crizotinib setting.

Lorlatinib, another potent next-generation *ALK* TKI, is generally used as *ALK* TKI post-alectinib and is the only *ALK* TKI that has this FDA indication based on a phase 2 trial demonstrating a median PFS of 5.5 months post-alectinib.²⁴ Most recently, ALTA-2, a single arm study of brigatinib in the post-alectinib (and post-ceritinib) setting reported an ORR of 26.2%. However, the lower limit of the 95% CI (18%) dropped below the 20% ORR null hypothesis.²⁵ Thus, ALTA-2 did not reach its primary endpoint. Furthermore, the median PFS achieved by brigatinib in the post-alectinib setting was 3.8 months (95% CI=1.9–5.4), which is numerically shorter than the median PFS achieved by lorlatinib in a similar setting.^{24,25} Hence, we project that the role of brigatinib in the treatment of advanced *ALK*+ NSCLC will continue to shrink, like ceritinib, which has been associated with significant toxicities and which possesses an even shorter median PFS of 16.8 months in the frontline setting based on ASCEND-4.²⁶

Our Final Perspectives on ALTA-3

ALTA-3 was designed at a time when crizotinib had begun to cede its role as the standard of care front-line treatment for advanced *ALK*+ NSCLC in the face of next-generation *ALK* TKIs (alectinib, brigatinib, lorlatinib). As stated in the rationale and perspective of the ALTA-3 trial, “if positive, the results of ALTA-3 will build on the ALTA trial data and reaffirm the optimal approach with brigatinib over alectinib in crizotinib-resistant patients”. If true, brigatinib would have at least retained, but not built on, a small role in the treatment of advanced *ALK*+ NSCLC in the ever-dwindling subset of patients who were treated with crizotinib as first-line or first *ALK* TKI treatment. With the near identical median PFS achieved by both alectinib and brigatinib in ALTA-3, and the disappointing results of ALTA-1L²³ and ALTA-2,²⁵ unfortunately we venture to speculate that brigatinib, despite being a highly potent *ALK* TKI, will fall victim to the breakneck pace of oncology and become a footnote in the treatment parlance of *ALK*+ NSCLC.

Disclosure

Professor Sai-Hong Ignatius Ou reports personal fees from Pfizer, AnHeart Therapeutics, JNJ/Janssen, DAVA Oncology LLP; stock ownership from Elevation Oncology and Turning Point Therapeutics, outside the submitted work. The authors report no other conflicts of interest in this work.

References

1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced *ALK*-positive lung cancer. *N Engl J Med*. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886
2. Kazandjian D, Blumenthal GM, Chen HY, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. *Oncologist*. 2014;19(10):e5–11. doi:10.1634/theoncologist.2014-0241
3. Malik SM, Maher VE, Bijwaard KE, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. *Clin Cancer Res*. 2014;20(8):2029–2034. doi:10.1158/1078-0432.CCR-13-3077

4. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med.* 2014;371(23):2167–2177. doi:10.1056/NEJMoa1408440
5. Ou SI, Nagasaka M, Brazel D, et al. Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? *Transl Oncol.* 2021;14(11):101191. doi:10.1016/j.tranon.2021.101191
6. Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomized, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2017;18(7):874–886. doi:10.1016/S1470-2045(17)30339-X
7. Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the Phase III ALUR study. *Ann Oncol.* 2018;29(6):1409–1416. doi:10.1093/annonc/mdy121
8. Wolf J, Helland Å, Oh IJ, et al. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. *ESMO Open.* 2022;7(1):100333. doi:10.1016/j.esmoop.2021.100333
9. Popat S, Liu G, Lu S, et al. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). *Future Oncol.* 2021;17(32):4237–4247. doi:10.2217/fon-2021-0608
10. Yang JC, Liu G, Lu S, et al. ALTA-3: a randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC. *Ann Oncol.* 2022;33(suppl_9):S1560–S1597. doi:10.1016/annonc/annonc1134
11. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. *Clin Cancer Res.* 2015;21(11):2436–2439. doi:10.1158/1078-0432.CCR-14-3157
12. Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. *J Clin Oncol.* 2016;34(7):661–668. doi:10.1200/JCO.2015.63.9443
13. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol.* 2016;17(2):234–242. doi:10.1016/S1470-2045(15)00488-X
14. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. *J Clin Oncol.* 2017;35(22):2490–2498. doi:10.1200/JCO.2016.71.5904
15. Zhang SS, Nagasaka M, Zhu VW, et al. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. *Lung Cancer.* 2021;158:126–136. doi:10.1016/j.lungcan.2021.06.012
16. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-Positive NSCLC: final results of phase 3 ALTA-1L Trial. *J Thorac Oncol.* 2021;16(12):2091–2108. doi:10.1016/j.jtho.2021.07.035
17. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med.* 2017;377(9):829–838. doi:10.1056/NEJMoa1704795
18. Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. *Lung Cancer.* 2020;139:195–199. doi:10.1016/j.lungcan.2019.11.025
19. Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomized phase 3 study. *Lancet Respir Med.* 2019;7(5):437–446. doi:10.1016/S2213-2600(19)30053-0
20. Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. *N Engl J Med.* 2020;383(21):2018–2029. doi:10.1056/NEJMoa2027187
21. Ou SH, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. *Ann Oncol.* 2014;25(2):415–422. doi:10.1093/annonc/mdt572
22. Ng TL, Narasimhan N, Gupta N, et al. Early-onset pulmonary events associated with brigatinib use in advanced NSCLC. *J Thorac Oncol.* 2020;15(7):1190–1199. doi:10.1016/j.jtho.2020.02.011
23. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK Inhibitor-naïve ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. *J Clin Oncol.* 2020;38(31):3592–3603. doi:10.1200/JCO.20.00505
24. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol.* 2018;19(12):1654–1667. doi:10.1016/S1470-2045(18)30649-1
25. Ou SI, Nishio M, Ahn MJ, et al. Efficacy of brigatinib in patients with advanced ALK-Positive NSCLC who progressed on alectinib or ceritinib: ALK in lung cancer trial of brigatinib-2 (ALTA-2). *J Thorac Oncol.* 2022;17(12):1404–1414. doi:10.1016/j.jtho.2022.08.018
26. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet.* 2017;389(10072):917–929. doi:10.1016/S0140-6736(17)30123-X

Lung Cancer: Targets and Therapy

Dovepress

Publish your work in this journal

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations.

Submit your manuscript here: <http://www.dovepress.com/lung-cancer-targets-therapy-journal>